Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Lung Neoplasms 2Colorectal Neoplasms 2Breast Neoplasms 2Stomach Neoplasms 1Sleep Initiation and Maintenance Disorders 1Sedentary Behavior 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Lymphoma 1Liver Neoplasms 1Invasive Breast Carcinoma 1High-Frequency Microsatellite Instability 1Head and Neck Carcinoma 1Fatigue 1Fallopian Tube Neoplasms 1Carcinoma, Hepatocellular 1Breast Carcinoma In Situ 1

Interventions

Carboplatin 87Paclitaxel 77Bevacizumab 38Topotecan 23liposomal doxorubicin 22Gemcitabine 22Taxes 21Cisplatin 17Drug Therapy 14Docetaxel 14Cyclophosphamide 14pembrolizumab 13Immunoglobulin G 12Disulfides 12veliparib 8rucaparib 8mirvetuximab soravtansine 8niraparib 7Albumin-Bound Paclitaxel 7sargramostim 6Filgrastim 6Erlotinib Hydrochloride 6Doxorubicin 6pazopanib 5Granulocyte-Macrophage Colony-Stimulating Factor 5Chemotherapy, Adjuvant 5CP protocol 5trebananib 4temsirolimus 4olaparib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fallopian Tube Neoplasms × Monitoring, Physiologic × Clear all
NCT03685695 2021-09-02

Physical Activity Monitored by Fitbit Charge 2 in Improving Quality of Life in Participants With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Roswell Park Cancer Institute

Phase 2 Completed
9 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡